Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | SHBG | P04278 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873115 | 0.83 | DRD2 (0.48) | DRD2HSD11B1 | |
| SCHEMBL9964031 | 0.83 | DRD2 (0.48) | DRD2HSD11B1 | |
| SCHEMBL1948828 | 0.83 | DRD2 (0.48) | DRD2HSD11B1 | |
| SCHEMBL1948829 | 0.83 | DRD2 (0.48) | DRD2HSD11B1 | |
| SCHEMBL16636006 | 0.82 | SRD5A1 (0.47) | DRD2HSD11B1 | |
| SCHEMBL15996614 | 0.78 | DRD2 (0.49) | DRD2HSD11B1ESR1ESR2 | |
| SCHEMBL22260050 | 0.78 | DRD2 (0.51) | DRD2HSD11B1 | |
| SCHEMBL18032810 | 0.78 | DRD2 (0.51) | DRD2HSD11B1 | |
| Bromide SCHEMBL9341130 | 0.76 | ESR1 (0.43) | DRD2SHBGESR1ESR2 | |
| SCHEMBL16635796 | 0.73 | PRCP (0.47) | DRD2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, INMT, INA | DRD2 213/4885SHBG 4601/4885HSD11B1 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.